• Explore /
  • Poster
  • / MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.

Abstract Video & Slides Poster

Authors

Tanios Bekaii-Saab

Tanios S. Bekaii-Saab

Mayo Clinic, Scottsdale, AZ

Tanios S. Bekaii-Saab , Eric Van Cutsem , Josep Tabernero , Salvatore Siena , Takayuki Yoshino , Yoshiaki Nakamura , Kanwal Pratap Singh Raghav , Andrea Cercek , Volker Heinemann , David E. Adelberg , Jorge Ramos , Shan Yang , Thierry Andre , John H Strickler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT05253651

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS3631)

DOI

10.1200/JCO.2023.41.16_suppl.TPS3631

Abstract #

TPS3631

Poster Bd #

327b

Abstract Disclosures

Similar Posters

First Author: Tanios S. Bekaii-Saab

First Author: John H. Strickler

First Author: John H. Strickler

First Author: Eiji Oki